

Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures

Tami D Lieberman¹, Kelly B Flett², Idan Yelin³, Thomas R Martin⁴, Alexander J McAdam⁵, Gregory P Priebe^{2,6,7} & Roy Kishony^{1,3}

Advances in sequencing technologies have enabled the identification of mutations acquired by bacterial pathogens during infection^{1–10}. However, it remains unclear whether adaptive mutations fix in the population or lead to pathogen diversification within the patient^{11,12}. Here we study the genotypic diversity of *Burkholderia dolosa* within individuals with cystic fibrosis by resequencing individual colonies and whole populations from single sputum samples. We find extensive intrasample diversity, suggesting that mutations rarely fix in a patient's pathogen population—instead, diversifying lineages coexist for many years. Under strong selection, multiple adaptive mutations arise, but none of these sweep to fixation, generating lasting allele diversity that provides a recorded signature of past selection. Genes involved in outer-membrane components, iron scavenging and antibiotic resistance all showed this signature of within-patient selection. These results offer a general and rapid approach for identifying the selective pressures acting on a pathogen in individual patients based on single clinical samples.

Two opposing models of within-patient bacterial evolution have been proposed: a 'dominant-lineage' model, in which beneficial mutations drive superior lineages to dominate in the population, and a 'diverse-community' model, in which adaptive lineages rise to intermediate frequency and coexist with other lineages (Fig. 1)^{11–14}. The diversity of within-patient pathogen populations has major implications for drug treatment and resistance^{7,15,16}, for inferring transmission networks^{8,9,17,18} and for understanding evolutionary processes^{13,19}. Here, to distinguish between these models and to understand the sources of genetic diversity, we compared the genomes of many bacterial cells of the same strain from the same clinical samples.

We focused on chronic infections with *B. dolosa*, a rare and deadly opportunistic pathogen that spread among 39 people with cystic fibrosis cared for at a single center in Boston starting in the 1990s (refs. 20,21). The airways of these patients were infected with very

similar starting strains, and surviving patients have been colonized for years. A previous retrospective study of single-colony isolates identified specific *B. dolosa* genes that evolved under strong selective pressures during the outbreak⁸. Now, using sputum samples collected during clinical care, we characterize contemporary intraspecies diversity in five individuals from this outbreak who have been infected with *B. dolosa* since the early 2000s.

We used two genomic approaches, colony resequencing (patient 1) and deep population sequencing (patients 1–5), to identify single-nucleotide mutations and their frequencies in single sputum samples. In our colony resequencing approach, we isolated dozens of colonies from a clinical sample and analyzed their genomes individually by alignment of reads to a *B. dolosa* reference genome, AU0158, a strain taken from a different patient in this outbreak. Because each colony originates from a single bacterium, this approach is equivalent to comparing different bacterial cells from the initial clinical sample. In the population sequencing approach^{22,23}, we pooled hundreds of colonies from each clinical sample and sequenced the pool with deep coverage (~450×). We then aligned reads to AU0158 and identified fixed mutations, appearing in all reads, and polymorphisms, appearing in only a fraction of the reads. To remove false positive polymorphic sites caused by systematic sequencing or alignment errors^{24,25}, we developed a set of thresholds and statistical tests that rejected polymorphic sites where the mutated and ancestral reads had significantly different properties^{22,23} (Supplementary Note). We calibrated this approach using an isogenic control for which we expected to detect no polymorphisms. For validation, we performed both methods on a single sample from patient 1, comparing diversity among 29 individual colonies to that detected with the population sequencing approach (Fig. 2). The population sequencing approach reliably detected polymorphisms where the minor allele frequency was greater than 3%, while decreasing the cost and labor required per sample.

We found that most of the mutations that arose during the course of infection did not fix, with sites remaining polymorphic within


¹Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA. ²Department of Medicine, Division of Infectious Diseases, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ³Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel. ⁴Department of Medicine, Division of Respiratory Diseases, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁵Department of Laboratory Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁶Department of Anesthesiology, Perioperative and Pain Medicine, Division of Critical Care Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁷Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Correspondence should be addressed to A.J.M. (alexander.mcadam@childrens.harvard.edu), G.P.P. (gregory.priebe@childrens.harvard.edu) or R.K. (roy_kishony@hms.harvard.edu).

Received 18 March; accepted 13 November; published online 8 December 2013; doi:10.1038/ng.2848

Figure 1 Alternative models of within-patient evolution. (a) In the dominant-lineage model of within-host evolution, lineages with beneficial mutations sweep to fixation (green lines), eliminating their less fit ancestors or other temporarily arising genotypes (dashed lines). In this model, most observed mutations will be fixed, and polymorphic mutations will be rare, representing only recent mutational events (magenta lines). (b) In the diverse-community model, lineages coexist and compete for long stretches of time. In this model, most sampled mutations will be polymorphic.

the patient. The colony resequencing approach performed for patient 1 identified 188 mutations occurring in some but not all isolates and only 10 mutations shared by all isolates. This dominance of polymorphisms, also seen in population sequencing of the same sample, strongly supports the diverse-community model (Fig. 3a,b). Similarly, for the four other patients, population sequencing on single samples identified a preponderance of polymorphisms compared to fixed mutations ($\geq 73\%$ of mutations; Fig. 3b). We found these excesses in polymorphisms despite the bias to overestimate mutations fixed during infection; some fixed mutations in a sputum sample might be polymorphic within the patient's airways or might have become fixed before patient colonization (Supplementary Fig. 1).

The observed genomic diversity is a reflection of multiple coexisting lineages. Investigating the community structure of *B. dolosa* within patient 1, we found a deeply branched phylogeny with six lineages separated by at least five lineage-specific mutations (Fig. 3a). On average, pairs of isolates from this sample differed by 26 mutations, and, of all 406 possible isolate pairs, only 1 was identical. Thus, even within a



single sputum sample, the population is so diverse that full identity of isolates is extremely rare.

In one patient (patient 5), the *B. dolosa* community had many more mutations than in other patients' populations ($P < 0.05$, Grubbs' test for outliers). This excess of mutations was due solely to increased transitions and not transversions, suggesting hypermutation ($P < 0.01$, Grubbs' test; Supplementary Fig. 2a). A search of the 199 mutated genes unique to the population of patient 5 identified a single mutation involved in DNA repair—a nonsynonymous mutation at a conserved position in *mutL*, defects of which are known to cause excess transitions²⁶ (Supplementary Fig. 2b). The excess mutations were enriched in synonymous mutations relative to the mutations identified in the other patients, further supporting the presence of hypermutation ($P < 0.001$; Supplementary Fig. 2c). Although hypermutation is a common phenotype in many pathogens, hypothesized to accelerate the evolution of antibiotic resistance^{27–30}, it has not previously been described in members of the *Burkholderia cepacia* complex³¹.

For how long have these diverging lineages coexisted? The time to the last common ancestor (LCA) of each nonhypermutating population from each patient³² can be estimated using the number of mutations accumulated since the LCA and the molecular clock previously





Figure 2 Two methods for studying genomic intraspecies diversity. (a) To study within-patient evolution, we cultured sputum samples from patients with cystic fibrosis on selective medium. In the colony resequencing approach (solid arrows; performed for one patient), we isolated multiple individual colonies from the same sample, independently called variants for each isolate via alignment of reads and compared variants between the isolates. In the deep population sequencing approach (dashed arrow; performed for five patients), we pooled hundreds of colonies from the same plate and analyzed the pool's genomic DNA. We identified positions on the genome where some reads, originating from different colonies on the plate, disagreed with an inferred ancestral genome (Online Methods). (b) Allele frequency estimates in population sequencing (y axis) versus colony resequencing (x axis) for the same sputum sample from patient 1 for each mutated position. Mutations are classified as either fixed or polymorphic. Some mutations found in the colony-based approach were below the threshold in frequency (3%) or confidence in the pool-based approach (dashed line). Slight jitter was added to the x and y coordinates for each point to improve visibility (up to 2% change). As an example, the insets at top and right display a summary of the raw data at the indicated genomic position. Population sequencing (right) at this position shows 70% of aligned reads supporting a T (orange) and 30% of aligned reads supporting a G (black), consistent with the corresponding number of colonies in the individual isolates (T, 22; G, 7). Reads from each isolate (top) are mostly of identical calls (all T or all G). Green indicates a single read in one isolate supporting an A, likely a sequencing error. For further comparison of the two methods, see Supplementary Figure 7.

Figure 3 Within-patient evolution leads to diversification not substitution. Mutations found in *B. dolosa* within-patient populations relative to the outgroup are classified as fixed (green) or polymorphic (magenta). An excess of polymorphic versus fixed mutations supports the diverse-community model over the dominant-lineage model. **(a)** A maximum-parsimony phylogeny of 29 isolates from the same sputum sample (patient 1) shows the coexistence of diverse sublineages separated by many single-nucleotide mutations accumulating since the LCA for this patient. Each isolate is represented by a dotted line. **(b)** The diverse-community model is also supported by the distribution of allele frequencies from population sequencing in five patient samples.



measured for this outbreak (2.1 SNPs/year; ref. 8). Given the phylogeny of isolates from patient 1, we calculated the distribution of the number of mutations since the LCA, d_{LCA} , across the population (**Fig. 4a**). The mean value of d_{LCA} across isolates, $\langle d_{LCA} \rangle$, was 19.6 single-nucleotide mutations per genome (95% confidence interval, CI = 18.3–20.8), suggesting that the LCA existed 9.3 years ago (CI = 8.7–9.9). This calculation places the LCA of the isolates from this sample slightly earlier than the first *B. dolosa* culture from this patient (7.6 years before sample collection), suggesting that the *B. dolosa* population in patient 1 has been diverging since or perhaps before initial colonization. Although the population sequencing approach could not provide a distribution of d_{LCA} , owing to a lack of information regarding linkage between mutations, we could still calculate $\langle d_{LCA} \rangle$ from the sum of the polymorphic mutation frequencies (see the **Supplementary Note** for derivation). Using this approach, the estimated time to the LCA for the population from patient 1 was 7.9 years. This value is slightly lower than that calculated with the clonal resequencing approach, likely owing to mutations left undetected by our conservative polymorphism caller (see the **Supplementary Note** for a discussion of error). For patients 2 and 4, the time to the LCA calculated by this population sequencing approach was several years less than the time since the first positive culture, suggesting fixation events sometime during these patients' histories (**Supplementary Table 1**). For all the patients, we estimated that diverging lineages coexisted in each for at least 5 years (**Fig. 4b**).

To explore the drivers of this long-coexisting diversity, we examined the identities of the evolving genes. Interestingly, we found that, within each sample, several *B. dolosa* genes carried 2–4 coexisting polymorphisms (**Supplementary Table 2**). This clustering represents a significant departure from a neutral model, given the number of mutations and

the distribution of gene lengths ($P < 0.005$ for patients 1–4; **Fig. 5a** and Online Methods). A similar analysis at the operon level further identified several operons enriched for polymorphisms (**Supplementary Fig. 3** and **Supplementary Table 3**). An enrichment of nonsynonymous mutations in these multidiverse genes and operons suggests that they are drivers of adaptive change *in vivo* (normalized ratio of nonsynonymous to synonymous mutations, dN/dS = 7.0, CI = 2.3–34.9; **Fig. 5b**). Polymorphisms are thus concentrated in genes undergoing adaptive evolution.

To understand why polymorphisms cluster in some genes, we asked whether coexisting mutations in the same gene appeared in different lineages or were linked in a double mutant. Examining the genomes of single isolates, we found no isolates with doubly mutated genes (**Supplementary Fig. 4**). Similarly, with population sequencing, in 10 of 11 cases where polymorphic positions were close enough on the genome to be covered by the same short sequencing reads, we did not find reads that contained both variants (**Fig. 5c** and **Supplementary Fig. 5**). In some of these cases, the ancestral genotype was completely purged from the population (**Fig. 5d**). Thus, diversification is driven by multiple adaptive mutations in the same genes evolving in parallel within individual patients.




Figure 4 Sublineages coexist within a patient for many years after divergence. **(a)** Histogram of the number (d_{LCA}) of single-nucleotide mutations found in isolates from patient 1 relative to their LCA. The black bar indicates the mean value of d_{LCA} across the isolates. **(b)** Value of $\langle d_{LCA} \rangle$ from the population sequencing data for patients 1–4 (Online Methods). In both panels, the axis at the top shows the relationship between d_{LCA} and years since the LCA, as calculated via the molecular clock (2.1 SNPs/year)⁸.




Figure 5 Coexistence of alternative adaptive mutations in the same sample highlights specific genes as drivers of within-host evolution. **(a)** Number of multidiverse genes observed in samples from patients 1–5 (blue bars) relative to a null expectation in which diverse sites are randomly distributed across the genome (histogram, 1,000 simulations). For patient 5, the number of multidiverse genes observed is not significant. **(b)** Canonical signal for selection, dN/dS, across the set of 16 genes and 3 operons showing a multidiverse signature in at least 1 patient (patients 1–4, 21 genes in total; blue) versus dN/dS across the set of genes not showing this signature (black). dN/dS of >1 indicates positive selection for amino acid changes. Error bars, 95% CI. See Online Methods for details on the calculation of dN/dS. **(c,d)** Linkage between nearby polymorphisms based on jointly overlapping short reads. Percentages of reads supporting the ancestral genotype, each of the single mutants and the double mutant are plotted for *wpbX* in patient 2 **(c)** and *gyrA* in patient 4 **(d)**. No reads supporting the double mutant were found ($n = 524$ and 415 , respectively) (see **Supplementary Fig. 5** for exception). **(e)** A network of patients and genes showing a multidiverse signature at least once in patients 1–4 (P1–P4). A gene is connected to a patient if it was mutated multiple times, had a single polymorphic mutation or had a single fixed mutation in that patient. Genes closer to the center of the network are mutated in more patients, representing common targets of *in vivo* pathogen selection, whereas genes connected to single patients may indicate patient-specific adaptation. Genes are labeled with their closest homolog and predicted biological role. The biological role of *rpoD* is unclassified because it was recently duplicated in the *B. cepacia* complex³⁹ (**Supplementary Table 2** and **Supplementary Note**).

These findings provide a new signature of past selective pressures detectable in a single clinical sample: the coexistence of multiple polymorphisms within the same gene in a clinical sample. Sixteen *B. dolosa* genes displayed this multidiverse signature, including genes with homologs involved in outer-membrane synthesis, antibiotic resistance, iron scavenging, oxygen sensing, amino acid synthesis, lactate use and stress response. Additionally, some genes with less characterized biological roles displayed a multidiverse signature, including two transcriptional regulators with unknown targets in *B. dolosa*, an uncharacterized glucoamylase and two genes that encode hypothetical proteins (**Supplementary Table 2**). A similar signature for selection was seen in three operons, two involved in lipopolysaccharide transport and one containing a two-component regulatory system with unknown targets (**Supplementary Table 3**). Selection on many of these elements can be rationalized by the relevance of their annotated functions to conditions to which the bacteria are exposed during the course of the infection. Yet, further investigation will be required to understand the potential roles of some of these genes in antibiotic resistance, fitness and other aspects of pathogenesis.

We found that many of the selective forces acting on the pathogen were the same across patients (**Fig. 5e**). Often, genes showing a multidiverse signature for selection in one patient also carried mutations in other patients ($P < 0.002$, hypergeometric test). A prominent example was *gyrA*, a well-studied target of quinolones, which was mutated in all patient populations. Further support for commonality in mutational trajectories across patients emerged from a significant overlap between this list of 16 multidiverse genes and 17 genes previously found to be under parallel evolution across a larger group

of patients, only 1 of whom (patient 2) was included in both studies ($P < 0.001$, hypergeometric test). Thus, the study of a single clinical sample can provide generalizable lists of the selective pressures felt within the human body.

Yet, some multidiverse signatures were patient specific. A penicillin-binding protein (BDAG_01166, homologous to PBP7) was affected by three nonsynonymous mutations in patient 1 but was not mutated in other patients. Such patient-specific parallel evolution might reflect patient-specific selective pressure or perhaps a fitness benefit dependent on previously acquired mutations. However, these hypotheses are hard to test because the genomic target for a selective force might include more than one gene. For example, populations from four of the five patients had a mutation in a homolog of the histidine kinase gene *fixL* (BDAG_01161; known to be under strong selection in these infections⁸), whereas the population from the fifth patient had a mutation in the corresponding response regulator gene.

To investigate the stability of these multidiverse signatures for selection, we collected a second sputum sample 14 d after initial sample collection from patient 2. Three of the four genes with the multidiverse signature at day 0 showed the same pattern at day 14. The absence of the signature in the fourth gene at the later time point does not reflect a relaxation in selection for mutant alleles but, rather, incomplete detection of genes under selection; this gene also had abundant nonsynonymous mutations at day 14, concentrated at a single nucleotide position (**Supplementary Fig. 6**). These results suggest that the multidiverse signature for selection is relatively stable and that multiple sample collections per patient can increase the sensitivity of detection.

Our results reject the dominant-lineage model of infection yet demonstrate that diversifying bacteria adapt under the pressure of natural selection. These observations are consistent with clonal interference: in large asexual populations, multiple beneficial mutations emerge and compete, impeding the ability of the corresponding lineages to reach fixation^{33–35}. In addition to large population size (10^8 cells/ml of sputum), the branched structure of the airways may further hinder the capacity of any adaptive lineage to dominate and fix, and the immune system or niche-specific adaptations might directly promote diversity. Diversified by any of these means, lineages may then continue to evolve in parallel against common selective forces.

As *B. dolosa* adapts to the airways of people with cystic fibrosis, mutations lead to diversification rather than fixation and replacement. Although it is possible that adaptive mutations lead to fixation more frequently in other infections, there is evidence that, at least in long-term colonization, diversity might be common^{14,36–38}. This long-term coexistence of diverse lineages records the genomic history of selection on the pathogen in its host. The ability to rapidly read off within-patient evolutionary history from the genotypic diversity within a single clinical sample may greatly accelerate the ability to survey the selective pressures acting on bacterial pathogens *in vivo*—shifting from an epidemic-level investigation to a single-patient paradigm.

URLs. *Burkholderia dolosa* sequencing project, http://www.broadinstitute.org/annotation/genome/burkholderia_dolosa.

METHODS

Methods and any associated references are available in the [online version of the paper](#).

Accession codes. Sequencing reads for all 29 isolates and 6 populations have been deposited in the NCBI Sequence Read Archive (SRA) under accession [SRP030656](#).

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We are grateful to J.-B. Michel and members of the Kishony laboratory for insightful discussions and support, to the team at the Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) for Illumina sequencing, to L. Williams and A. Palmer for discussions and technical assistance, and to Y. Gerardin, J. Meyer, L. Stone and R. Ward for their comments on the manuscript. T.D.L. and G.P.P. were supported in part by grants from the Cystic Fibrosis Foundation (LIEBER12H0 to T.D.L. and PRIEBE1310 to G.P.P.). This work was funded in part by the US National Institutes of Health (GM081617 to R.K.), the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (NERCE; U54 AI057159 to R.K.) and Hoffman-LaRoche.

AUTHOR CONTRIBUTIONS

T.D.L., A.J.M., G.P.P. and R.K. designed the study. A.J.M. and T.R.M. collected clinical samples. K.B.F., T.R.M., A.J.M. and G.P.P. conducted chart review and provided medical information. T.D.L. performed experiments. T.D.L., I.Y. and R.K. wrote the sequence analysis scripts. T.D.L. and R.K. analyzed the data. T.D.L., A.J.M., G.P.P. and R.K. interpreted the results and wrote the manuscript.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

1. Mwangi, M.M. *et al.* Tracking the *in vivo* evolution of multidrug resistance in *Staphylococcus aureus* by whole-genome sequencing. *Proc. Natl. Acad. Sci. USA* **104**, 9451–9456 (2007).

2. Comas, I. *et al.* Whole-genome sequencing of rifampicin-resistant *Mycobacterium tuberculosis* strains identifies compensatory mutations in RNA polymerase genes. *Nat. Genet.* **44**, 106–110 (2012).
3. Ford, C.B. *et al.* Use of whole genome sequencing to estimate the mutation rate of *Mycobacterium tuberculosis* during latent infection. *Nat. Genet.* **43**, 482–486 (2011).
4. Kennemans, L. *et al.* *Helicobacter pylori* genome evolution during human infection. *Proc. Natl. Acad. Sci. USA* **108**, 5033–5038 (2011).
5. Young, B.C. *et al.* Evolutionary dynamics of *Staphylococcus aureus* during progression from carriage to disease. *Proc. Natl. Acad. Sci. USA* **109**, 4550–4555 (2012).
6. Huse, H.K. *et al.* Parallel evolution in *Pseudomonas aeruginosa* over 39,000 generations *in vivo*. *MBio* **1**, e00199–10 (2010).
7. Snitkin, E.S. *et al.* Tracking a hospital outbreak of carbapenem-resistant *Klebsiella pneumoniae* with whole-genome sequencing. *Science Transl. Med.* **4**, 148ra116 (2012).
8. Lieberman, T.D. *et al.* Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. *Nat. Genet.* **43**, 1275–1280 (2011).
9. Didelot, X. *et al.* Genomic evolution and transmission of *Helicobacter pylori* in two South African families. *Proc. Natl. Acad. Sci. USA* **110**, 13880–13885 (2013).
10. Wilson, D.J. Insights from genomics into bacterial pathogen populations. *PLoS Pathog.* **8**, e1002874 (2012).
11. Workentine, M. & Surette, M.G. Complex *Pseudomonas* population structure in cystic fibrosis airway infections. *Am. J. Respir. Crit. Care Med.* **183**, 1581–1583 (2011).
12. Nguyen, D. & Singh, P.K. Evolving stealth: genetic adaptation of *Pseudomonas aeruginosa* during cystic fibrosis infections. *Proc. Natl. Acad. Sci. USA* **103**, 8305–8306 (2006).
13. Chung, J.C. *et al.* Genomic variation among contemporary *Pseudomonas aeruginosa* isolates from chronically infected cystic fibrosis patients. *J. Bacteriol.* **194**, 4857–4866 (2012).
14. Workentine, M.L. *et al.* Phenotypic heterogeneity of *Pseudomonas aeruginosa* populations in a cystic fibrosis patient. *PLoS ONE* **8**, e60225 (2013).
15. Foweraker, J.E., Laughton, C.R., Brown, D.F. & Bilton, D. Phenotypic variability of *Pseudomonas aeruginosa* in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. *J. Antimicrob. Chemother.* **55**, 921–927 (2005).
16. Sun, G. *et al.* Dynamic population changes in *Mycobacterium tuberculosis* during acquisition and fixation of drug resistance in patients. *J. Infect. Dis.* **206**, 1724–1733 (2012).
17. Harris, S.R. *et al.* Whole-genome sequencing for analysis of an outbreak of methicillin-resistant *Staphylococcus aureus*: a descriptive study. *Lancet Infect. Dis.* **13**, 130–136 (2013).
18. Walker, T.M. *et al.* Whole-genome sequencing to delineate *Mycobacterium tuberculosis* outbreaks: a retrospective observational study. *Lancet Infect. Dis.* **13**, 137–146 (2013).
19. Hansen, S.K. *et al.* Evolution and diversification of *Pseudomonas aeruginosa* in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. *ISME J.* **6**, 31–45 (2012).
20. Vermis, K. *et al.* Proposal to accommodate *Burkholderia cepacia* genomovar VI as *Burkholderia dolosa* sp. nov. *Int. J. Syst. Evol. Microbiol.* **54**, 689–691 (2004).
21. Kalish, L.A. *et al.* Impact of *Burkholderia dolosa* on lung function and survival in cystic fibrosis. *Am. J. Respir. Crit. Care Med.* **173**, 421–425 (2006).
22. Cibulskis, K. *et al.* Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat. Biotechnol.* **31**, 213–219 (2013).
23. Barrick, J.E. & Lenski, R.E. Genome-wide mutational diversity in an evolving population of *Escherichia coli*. *Cold Spring Harb. Symp. Quant. Biol.* **74**, 119–129 (2009).
24. Pickrell, J.K., Gilad, Y. & Pritchard, J.K. Comment on “Widespread RNA and DNA sequence differences in the human transcriptome”. *Science* **335**, 1302 (2012).
25. Nakamura, K. *et al.* Sequence-specific error profile of Illumina sequencers. *Nucleic Acids Res.* **39**, e90 (2011).
26. Oliver, A. & Mena, A. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. *Clin. Microbiol. Infect.* **16**, 798–808 (2010).
27. Oliver, A., Canton, R., Campo, P., Baquero, F. & Blazquez, J. High frequency of hypermutable *Pseudomonas aeruginosa* in cystic fibrosis lung infection. *Science* **288**, 1251–1254 (2000).
28. Jolivet-Gougeon, A. *et al.* Bacterial hypermutation: clinical implications. *J. Med. Microbiol.* **60**, 563–573 (2011).
29. Hoboth, C. *et al.* Dynamics of adaptive microevolution of hypermutable *Pseudomonas aeruginosa* during chronic pulmonary infection in patients with cystic fibrosis. *J. Infect. Dis.* **200**, 118–130 (2009).
30. Marvig, R.L., Johansen, H.K., Molin, S. & Jelsbak, L. Genome analysis of a transmissible lineage of *Pseudomonas aeruginosa* reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. *PLoS Genet.* **9**, e1003741 (2013).
31. Pope, C.F., Gillespie, S.H., Moore, J.E. & McHugh, T.D. Approaches to measure the fitness of *Burkholderia cepacia* complex isolates. *J. Med. Microbiol.* **59**, 679–686 (2010).
32. Kingman, J.F.C. On the genealogy of large populations. *J. Appl. Probab.* **19**, 27–43 (1982).
33. Fogle, C.A., Nagle, J.L. & Desai, M.M. Clonal interference, multiple mutations and adaptation in large asexual populations. *Genetics* **180**, 2163–2173 (2008).

34. Gerrish, P.J. & Lenski, R.E. The fate of competing beneficial mutations in an asexual population. *Genetica* **102–103**, 127–144 (1998).
35. Hegreness, M., Shores, N., Hartl, D. & Kishony, R. An equivalence principle for the incorporation of favorable mutations in asexual populations. *Science* **311**, 1615–1617 (2006).
36. Mowat, E. *et al.* *Pseudomonas aeruginosa* population diversity and turnover in cystic fibrosis chronic infections. *Am. J. Respir. Crit. Care Med.* **183**, 1674–1679 (2011).
37. Schloissnig, S. *et al.* Genomic variation landscape of the human gut microbiome. *Nature* **493**, 45–50 (2013).
38. Ashish, A. *et al.* Extensive diversification is a common feature of *Pseudomonas aeruginosa* populations during respiratory infections in cystic fibrosis. *J. Cyst. Fibros.* doi:10.1016/j.jcf.2013.04.003 (1 May 2013).
39. Menard, A., de Los Santos, P.E., Graindorge, A. & Cournoyer, B. Architecture of *Burkholderia cepacia* complex $\sigma 70$ gene family: evidence of alternative primary and clade-specific factors, and genomic instability. *BMC Genomics* **8**, 308 (2007).

ONLINE METHODS

Study cohort and sample collection. An epidemic clone of *B. dolosa* infected and colonized 39 individuals with cystic fibrosis in the Boston area over a 20-year period²¹. We studied *B. dolosa* intrapatient diversity in five surviving individuals still infected with *B. dolosa*. All subjects were male, had homozygous Δ F508 alterations, had not received lung transplants, were between 21 and 35 years of age, and had been colonized for between 7 and 10 years at the time of sample collection (**Supplementary Table 1**). Longitudinal microbial isolates from patient 2 were also included in a previous retrospective study (patient J in ref. 8).

For patient 1, both the colony resequencing and deep population sequencing approaches were performed on a single sputum sample (P1). For patient 2, population deep sequencing was performed on each of two sputum samples (P2 and P2T), collected 14 d apart. Between collections, patient 2 was treated for a pulmonary exacerbation, including a change in antibiotic regimen, but his condition did not improve, and *B. dolosa* density did not decrease. For patients 3–5, population sequencing was performed on a single sputum sample from each patient (P3–P5).

Expectorated sputum samples were collected at Boston Children's Hospital after written informed consent was obtained under protocols approved by the institutional review boards at Boston Children's Hospital and Harvard Medical School. Samples were liquefied with dithiothreitol⁴⁰ and stored at -80°C in 20% glycerol. *B. dolosa* was cultured from frozen samples. For population sequencing, a plate with 5,000 to 30,000 small colonies was chosen from a serial dilution. See the **Supplementary Note** for more details on sample preparation.

Illumina sequencing. Genomic DNA was extracted using the MoBio UltraClean Microbial DNA Isolation kit according to the manufacturer's instructions. Genomic libraries were constructed and barcoded using the Illumina-compatible Epicentre Nextera DNA Sample Prep kit following the manufacturer's instructions (PCR amplification in the Nextera preparation does not introduce false positive polymorphisms; **Supplementary Note**). Genomic libraries were sequenced on the Illumina HiSeq 2000 platform by the Partners HealthCare Center for Personalized Genetic Medicine. Individual colonies were sequenced using single-end 50-bp reads, and pooled samples were sequenced using paired-end 50-bp reads. Reads were aligned to the *B. dolosa* draft genome AU0158 (GenBank accession [AAKY000000000](http://www.ncbi.nlm.nih.gov/nuccore/AAKY000000000); see URLs), belonging to an isolate recovered from patient 0 of the outbreak. AU0158 consists of 233 contigs on 3 scaffolds (*B. dolosa* has 3 chromosomes). Standard approaches were used for read filtering and alignment (**Supplementary Note**). See **Supplementary Table 4** for coverage statistics.

Mutation identification, colony resequencing. An outgroup of three outbreak strains (A-0-0, G-9-8 and N-12-6d- δ ; previously sequenced in ref. 8) was included in the analysis to identify mutations fixed among the 29 isolates from patient 1. We considered genomic positions at which at least one pair of isolates was discordant on the called base and both members of the pair had FQ scores less than -40 (FQ scores are generated by SAMtools⁴¹; lower values indicate agreement between reads). Genomic positions for which multiple isolates had multiple calls per isolate were discarded (likely duplication not represented in the reference). A best call was forced for each isolate (**Supplementary Table 5**), and the list of concatenated SNPs was inputted into the dnaps program in PHYLIP v3.69 (ref. 42). The resulting phylogeny was visualized using Figtree (**Fig. 3b**).

Mutation identification, deep population sequencing. Fixed mutations in each patient's population were called using the same procedure as for individual isolates, with a stricter quality score threshold (FQ < -282). Custom MATLAB scripts and SAMtools-generated pileup files were used to summarize all calls and their related quality scores at each genomic position (for example, base quality, mapping quality and tail distance; **Supplementary Note**). Using the isogenic control, multiple isolates from patient 1 and an interactive MATLAB environment that enabled investigation of the raw data, we developed a set of filters to identify true positive polymorphic positions with minor allele frequency greater than 3% (**Supplementary Table 6**). Thresholds were chosen to minimize false positives. See **Supplementary Figures 7 and 8** and the **Supplementary Note** for descriptions of the filters and sensitivity analysis.

Estimation of $\langle d_{\text{LCA}} \rangle$. For the colony-based approach, d_{LCA} was calculated for each isolate as the number of mutations received by that isolate normalized by the size of the callable genome. For this approach, the callable genome was the set of genomic positions with FQ score of < -40 . The CI for $\langle d_{\text{LCA}} \rangle$ presented for this approach was calculated according to a Poisson distribution. For the pool-based approach, $\langle d_{\text{LCA}} \rangle$ was calculated as the sum of the mutation frequencies at each polymorphic position called within that population, normalized by the size of the callable genome (**Supplementary Note**). For the pool-based approach, we defined the callable genome as the set of positions that met the chosen thresholds for coverage, average base quality, average mapping quality and average tail distance for each strand, irrespective of nucleotide call. See **Supplementary Figure 6b** and the **Supplementary Note** for a discussion of sources of error in estimating $\langle d_{\text{LCA}} \rangle$ and time since the LCA.

Detection of parallel evolution within patients. We defined genes with a multidiverse signature of selection as genes for which within the same sputum sample there were multiple polymorphisms and multiple polymorphisms per 2,000 bp (to account for the fact that long genes are more likely to be mutated multiple times by chance). To determine whether the number of genes showing this signature represented a significant departure from what would be expected in a neutral model, we performed for each sputum sample 1,000 simulations in which we randomly shuffled the polymorphisms found across the callable genome and calculated how many genes showed a signature of selection (**Fig. 5a**).

This analysis was repeated at the operon and pathway levels, using the free version of FgenesB to identify operons and subsystem annotations provided by SEED⁴³ as pathways (**Supplementary Fig. 3**). As in the gene analysis, we considered operons and pathways to have a signature of selection if they had both multiple polymorphisms and multiple polymorphisms per 2,000 nucleotides within the same patient.

dN/dS. Mutations were classified as nonsynonymous (N) or synonymous (S) according to annotations provided in the GenBank file. For ORFs in the draft genome without a provided reading frame, we used BLAST and RefSeq to identify the most likely reading frame in the neighborhood of the found mutations. For each dN/dS calculation, we used the particular spectrum of mutations observed to calculate the expected N/S ratio (for example, across the *B. dolosa* genome, A>C mutations are 10.6 times more likely to cause a nonsynonymous mutation than G>A mutations). The observed value of the N/S ratio was divided by this expectation to give dN/dS. CIs and *P* values were calculated according to binomial sampling. The dN/dS value reported (**Fig. 5b**) groups together the mutations found in genes and operons under selection; the same calculation for only genes gave a dN/dS value of 5.9 (95% CI = 1.9–29.6).

Parallel evolution across patients. We used the hypergeometric distribution to assess the significance of overlap between gene sets. Of the 225 *B. dolosa* genes mutated in patients 1–4, only 16 showed the multidiverse signature of selection within patients and only 29 genes were mutated in multiple patients (fixed or polymorphic), yet 7 genes were in common between these lists ($P = 0.0015$). Similarly, 13 of these 225 genes were also found on a list of 17 genes evolved in parallel across patients in a previous study⁸. These 13 genes were enriched in the 16 genes under selection in this study (5-gene overlap; $P = 0.0009$). When this analysis was repeated without mutations from patient 2 (this patient was also included in the retrospective study), 11 of the 189 mutated genes were found in the previous study, and 13 genes showed a multidiverse signature of selection. The overlap between these lists of 11 and 13 genes was smaller but still significant (4 genes; $P = 0.0035$).

40. Guss, A.M. *et al.* Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. *ISME J.* **5**, 20–29 (2011).

41. Li, H. *et al.* The sequence alignment/map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).

42. Felsenstein, J. PHYLIP-Phylogeny Inference Package (Version 3.2). *Cladistics* **5**, 164–166 (1989).

43. Aziz, R.K. *et al.* The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* **9**, 75 (2008).